Institute of Transfusion Medicine and Immunology, Heidelberg University, Mannheim, Germany.
J Interferon Cytokine Res. 2011 Aug;31(8):639-42. doi: 10.1089/jir.2010.0141. Epub 2011 Mar 2.
Kidney transplant recipients with the interleukin-6 (IL-6) GGG/GGG promoter (-597/-572/-174)genotype were shown to have a better long-term outcome. Further, the same (-597/-572/-174)genotype was found to be associated with less IL-6 production in healthy control subjects. To verify this observation in potential kidney transplant recipients, IL-6 production was analyzed in 85/142 hemodialysis patients. We could not confirm an impaired IL-6 secretion in carriers of the GGG/GGG (-597/-572/-174)genotype and propose a significantly lower IL-6 production in hemodialysis patients versus healthy control subjects to explain this. However, we suggest subsequent studies of IL-6 production in kidney allograft recipients to further elucidate the pathophysiological relevance of IL-6 for transplant outcome.
已有研究表明,白细胞介素-6(IL-6)GGG/GGG 启动子(-597/-572/-174)基因型的肾移植受者具有更好的长期预后。此外,相同的(-597/-572/-174)基因型与健康对照个体中 IL-6 产生减少有关。为了在潜在的肾移植受者中验证这一观察结果,我们分析了 85/142 名血液透析患者的 IL-6 产生情况。我们不能证实 GGG/GGG(-597/-572/-174)基因型携带者的 IL-6 分泌受损,并提出血液透析患者的 IL-6 产生明显低于健康对照者,以解释这一点。然而,我们建议对肾移植受者的 IL-6 产生进行进一步研究,以进一步阐明 IL-6 对移植结果的病理生理相关性。